<\/p>\n
\ud83d\udca1 Hurtigt svar<\/strong><\/p>\n Etibo<\/strong> er lapatinib 250 mg<\/strong>, en dual HER2\/EGFR tyrosine kinase inhibitor<\/strong> for advanced or metastatic HER2-positive breast cancer<\/strong>. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n Etibo is a branded generic of lapatinib<\/strong> 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2)<\/strong> og EGFR (ErbB1)<\/strong>. Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.<\/p>\n Kritisk:<\/strong> Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol \u2014 typically after trastuzumab resistance develops.<\/p>\n Meget almindelige:<\/strong> diarrhoea (60\u201380%), rash (40\u201360%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).<\/p>\n Alvorlige:<\/strong> hepatotoxicity<\/strong> (monitor LFTs), cardiotoxicity \/ reduced LVEF<\/strong> (5\u20136%), QT prolongation, interstitial lung disease (rare but serious).<\/p>\n Alvorlige:<\/strong> severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.<\/p>\n Store at room temperature (15\u201330 \u00b0C), away from moisture. Keep in original packaging. Keep out of reach of children.<\/p>\n Advanced\/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.<\/p>\n Food increases lapatinib absorption 4\u20135\u00d7, making dosing unpredictable. Standard is consistent fasting \u2014 1 hour before or after food \u2014 at a fixed time each day.<\/p>\n Common, often grade 1\u20132; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.<\/p>\n About 5\u20136% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.<\/p>\n Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.<\/p>\n Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.<\/p>\n HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.<\/p>\n For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) have since largely supplanted it in first-world oncology \u2014 lapatinib remains important where newer agents are unavailable.<\/p>\n \u2695\ufe0f Medicinsk ansvarsfraskrivelse:<\/strong> Informationen er vejledende og erstatter ikke l\u00e6gevejledning. Konsulter en l\u00e6ge f\u00f8r du p\u00e5begynder, afslutter eller \u00e6ndrer medicin, is\u00e6r ved kr\u00e6ftbehandling, hormonbehandlinger og receptpligtige produkter.<\/p>\n<\/div>\n <\/p>\n Andre onkologiske l\u00e6gemidler p\u00e5 lager sammen med dette produkt:<\/p>\n \u2705 Targets cancer cells Etibo contains Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Hvorfor bestille fra MedsBase<\/h3>\n
What Is Etibo?<\/strong><\/h2>\n
Klinisk anvendelse<\/strong><\/h2>\n
\n
S\u00e5dan indtages<\/strong><\/h2>\n
\n
Bivirkninger<\/strong><\/h2>\n
Who Should Not Take Etibo<\/strong><\/h2>\n
\n
L\u00e6gemiddelinteraktioner<\/strong><\/h2>\n
\n
Opbevaring<\/strong><\/h2>\n
Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n
When is lapatinib used?<\/h3>\n
Why take on empty stomach?<\/h3>\n
How bad is the diarrhoea?<\/h3>\n
Will lapatinib damage my heart?<\/h3>\n
Can I take lapatinib with trastuzumab?<\/h3>\n
What about fertility?<\/h3>\n
Why is this in the Women's Health category?<\/h3>\n
Is lapatinib still first-line?<\/h3>\n
Relaterede produkter til kvinders sundhed<\/h3>\n
\n
Relaterede alternativer<\/h3>\n
\n
\n\u2705 Inhibits tumor growth
\n\u2705 Treats breast cancer
\n\u2705 Blocks HER2 receptors
\n\u2705 Forbedrer overlevelsesrater<\/p>\n